Pfizer's Groton cuts slightly top earlier estimates; Warner Chilcott sees lower-than-expected 2013 earnings;

By Tracy Staton Feb 11, 2013 7:27am

@FiercePharma: Corks pop at Sanofi as FDA nixes Novo's Lantus challenger. Article | Follow @FiercePharma

@EricPFierce: New Celgene drug for multiple myeloma expected to help fuel expansion of market to $7.2 billion. News | Follow @EricPFierce

@AlisonBFierce: A genetically modified smallpox vaccine shrunk tumors in liver cancer patients and extended survival more than a year. More | Follow @AlisonBFierce

> Pfizer ($PFE) shrank its Groton, CT, workforce more than expected during a company restructuring, with around 3,300 people now employed there compared with its target of 3,400; that's down from 4,500 two years ago. Report

> Warner Chilcott ($WCRX) put up a 2013 forecast that fell short of analyst estimates because of increases in R&D expenses related to late-stage products. Report

> California drugmaker Titan Medical Enterprises was ordered to shut down after a U.S. judge ruled that the company didn't follow FDA manufacturing rules and sold unapproved drugs. Report

> Takeda and partner Sucampo sued Anchen and Par Pharmaceuticals for patent infringement after the generics makers asked FDA to approve copies of the bowel treatment Amitiza. Report

> Celgene's ($CELG) multiple myeloma drug Revlimid won approval from Japanese regulators for patients who've failed on at least one prior therapy. Report

> Pharmaceutical exports to Iran dropped by half last year, new data show, suggesting that economic sanctions are affecting "humanitarian" trade as well as other goods. Report

> Roman Catholic bishops rejected the Obama administration's attempt at a compromise on health-plan coverage of contraceptives. Report

Medical Device News

@FierceMedDev: Israeli team advances genetic device to perform DNA diagnosis. Report | Follow @FierceMedDev

@MarkHFierce: Indiana offers a way to work around the device tax, rather than focusing on repealing it. More | Follow @MarkHFierce

@DamianFierce: Pfizer's ongoing R&D slash and burn could be good news for CROs. Story | Follow @DamianFierce

> Japan's regulators push for quicker device approval process. News

> Indiana mulls industry tax break to counter federal device tax. Report

Biotech News

@FierceBiotech: Sanofi move to acquire more shares of Regeneron triggers market buzz. Report | Follow @FierceBiotech

@JohnCFierce: Tresiba news underscores how high the FDA sets the bar on diabetes. Hard for biotechs to play in a field like this. News | Follow @JohnCFierce

@RyanMFierce: 'Mercenary' coders crowd-sourced for immunology research software. Report | Follow @RyanMFierce

> Bayer hands off FDA app as pulmonary hypertension drug race heats up. Story

> Spurning panel endorsement, FDA rejects Novo's long-acting insulin Tresiba. Article

CRO News

> GSK ups the ante for trial transparency. Story

> Struggling Cardiome recruits Quintiles to handle heart drug. More

> Struggling Cardiome recruits Quintiles to handle heart drug. News

> QPS snags Florida trial site amid buying spree. Report

> Pfizer's Singapore slash and burn could be good news for CROs. Article

Biotech IT News

> Trials software outfit BioClinica reports annual results (for the last time?) Item